<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01149525</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2009/13</org_study_id>
    <nct_id>NCT01149525</nct_id>
  </id_info>
  <brief_title>Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis</brief_title>
  <acronym>FACTSEP</acronym>
  <official_title>A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the efficacy of L-carnitine versus placebo in the
      treatment of fatigue in multiple sclerosis patients. This study will randomize 60 patients in
      a cross-over design. This study is sponsored by academic French health institutions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fatigue is one of the most frequent disabling symptom in Multiple Sclerosis (MS). L-Carnitine
      is currently used in the symptomatic treatment of fatigue after chemotherapy in patients with
      cancers. It is also empirically used by numerous MS centers in the treatment of fatigue.
      However, this practice is not evidence-based (Cochrane review 2010). This study will evaluate
      the efficacy of L-carnitine versus placebo in the treatment of fatigue in MS patients in a
      randomized double blind national multicenter cross-over trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Global score on the 21 item Modified Fatigue Impact Scale (MFIS, translated and validated in French).</measure>
    <time_frame>Three months and nine months (2 periods of 3 months on treatment/placebo separated by a wash-out period of 3 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS)</measure>
    <time_frame>Three and nine months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Visual Analogic Scale (VAS)</measure>
    <time_frame>Three and nine months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>physical dimension scale of MFIS</measure>
    <time_frame>Three and nine months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SEP59 scale of quality of life (Multiple Sclerosis Quality Of Life scale validated in french)</measure>
    <time_frame>Three and nine months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral solution of L-Carnitine, 4g per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Similar oral solution without L-Carnitine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Carnitine</intervention_name>
    <description>2g oral solution , twice per day (morning/evening), during 3 months</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral solution, twice per day (morning/evening), during 3 months</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years old and older

          -  Relapsing remitting (RR) secondary progressive (SP) or primary progressive multiple
             sclerosis according to McDonald 2005 (Polman) MS diagnostic criteria.

          -  Affected of fatigue for more than 3 months with global score on Modified Fatigue
             Impact Scale (MFIS)&gt;45.

          -  Indication of treatment of fatigue to the appreciation of the neurologist.

          -  Expanded Disability Status Scale (EDSS) not exceeding 6.0.

          -  Information and comprehensive agreement signed by patient and the investigator.

          -  Subject affiliated to health insurance coverage.

        Exclusion Criteria:

          -  Patients with serious unstable disease :

               -  recurrent or serious relapses

               -  rapidly ongoing disability impairment in the preceding 6 months

               -  serious or non stabilized depression

          -  Patients starting a new disease modifying therapy, immunosuppression or antidepressant
             therapy less than 3 months ago or not stabilized.

          -  Patients with a treatment of fatigue or of other condition that may interfere with
             fatigue evaluation to the appreciation of the neurologist.

          -  Energy drinks consumption or toxicomania.

          -  All other reasons to the opinion of the neurologist that may impair study management,
             especially patient compliance, neuro-psychological disorders that may input
             questionnaires filling.

          -  Person under protection of the law.

          -  Participation in other clinical trials (allowing for exceptions, after recommendation
             from the scientific council).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Christophe OUALLET, MD-PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Geneviève CHENE, MD-PhD</last_name>
    <role>Study Chair</role>
    <affiliation>USMR (University Hospital, Bordeaux)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital, Hospital Pellegrin</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Fort de France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Hospital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Hospital Central</name>
      <address>
        <city>Nancy</city>
        <zip>54034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Hospital Laënnec</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital, Hospital Pasteur</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Tejani AM, Wasdell M, Spiwak R, Rowell G, Nathwani S. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007280. doi: 10.1002/14651858.CD007280.pub2. Review. Update in: Cochrane Database Syst Rev. 2012;5:CD007280.</citation>
    <PMID>20166093</PMID>
  </reference>
  <reference>
    <citation>Bakshi R. Fatigue associated with multiple sclerosis: diagnosis, impact and management. Mult Scler. 2003 Jun;9(3):219-27. Review.</citation>
    <PMID>12814166</PMID>
  </reference>
  <reference>
    <citation>Filippi M, Rocca MA, Colombo B, Falini A, Codella M, Scotti G, Comi G. Functional magnetic resonance imaging correlates of fatigue in multiple sclerosis. Neuroimage. 2002 Mar;15(3):559-67.</citation>
    <PMID>11848698</PMID>
  </reference>
  <reference>
    <citation>Oken BS, Kishiyama S, Zajdel D, Bourdette D, Carlsen J, Haas M, Hugos C, Kraemer DF, Lawrence J, Mass M. Randomized controlled trial of yoga and exercise in multiple sclerosis. Neurology. 2004 Jun 8;62(11):2058-64.</citation>
    <PMID>15184614</PMID>
  </reference>
  <reference>
    <citation>Pucci E, Branãs P, D'Amico R, Giuliani G, Solari A, Taus C. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002818. Review.</citation>
    <PMID>17253480</PMID>
  </reference>
  <reference>
    <citation>Krupp LB, Coyle PK, Doscher C, Miller A, Cross AH, Jandorf L, Halper J, Johnson B, Morgante L, Grimson R. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995 Nov;45(11):1956-61.</citation>
    <PMID>7501140</PMID>
  </reference>
  <reference>
    <citation>van Diemen HA, Polman CH, van Dongen TM, van Loenen AC, Nauta JJ, Taphoorn MJ, van Walbeek HK, Koetsier JC. The effect of 4-aminopyridine on clinical signs in multiple sclerosis: a randomized, placebo-controlled, double-blind, cross-over study. Ann Neurol. 1992 Aug;32(2):123-30.</citation>
    <PMID>1510353</PMID>
  </reference>
  <reference>
    <citation>Stankoff B, Waubant E, Confavreux C, Edan G, Debouverie M, Rumbach L, Moreau T, Pelletier J, Lubetzki C, Clanet M; French Modafinil Study Group. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology. 2005 Apr 12;64(7):1139-43.</citation>
    <PMID>15824337</PMID>
  </reference>
  <reference>
    <citation>Tomassini V, Pozzilli C, Onesti E, Pasqualetti P, Marinelli F, Pisani A, Fieschi C. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004 Mar 15;218(1-2):103-8.</citation>
    <PMID>14759641</PMID>
  </reference>
  <reference>
    <citation>Wingerchuk DM, Benarroch EE, O'Brien PC, Keegan BM, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M. A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis. Neurology. 2005 Apr 12;64(7):1267-9.</citation>
    <PMID>15824361</PMID>
  </reference>
  <reference>
    <citation>Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler. 2006 Jun;12(3):321-4.</citation>
    <PMID>16764345</PMID>
  </reference>
  <reference>
    <citation>Pittion-Vouyovitch S, Debouverie M, Guillemin F, Vandenberghe N, Anxionnat R, Vespignani H. Fatigue in multiple sclerosis is related to disability, depression and quality of life. J Neurol Sci. 2006 Apr 15;243(1-2):39-45. Epub 2006 Jan 24.</citation>
    <PMID>16434057</PMID>
  </reference>
  <reference>
    <citation>Debouverie M, Pittion S. [Fatigue and episodic exhaustion as a feature of multiple sclerosis]. Rev Neurol (Paris). 2006 Mar;162(3):295-7. French.</citation>
    <PMID>16585884</PMID>
  </reference>
  <reference>
    <citation>Richardson BA, Flack VF. The analysis of incomplete data in the three-period two-treatment cross-over design for clinical trials. Stat Med. 1996 Jan 30;15(2):127-43.</citation>
    <PMID>8614750</PMID>
  </reference>
  <reference>
    <citation>GRIZZLE JE. THE TWO-PERIOD CHANGE-OVER DESIGN AN ITS USE IN CLINICAL TRIALS. Biometrics. 1965 Jun;21:467-80.</citation>
    <PMID>14338679</PMID>
  </reference>
  <reference>
    <citation>Kieser M, Friede T. Re-calculating the sample size in internal pilot study designs with control of the type I error rate. Stat Med. 2000 Apr 15;19(7):901-11.</citation>
    <PMID>10750058</PMID>
  </reference>
  <reference>
    <citation>Graziano F, Bisonni R, Catalano V, Silva R, Rovidati S, Mencarini E, Ferraro B, Canestrari F, Baldelli AM, De Gaetano A, Giordani P, Testa E, Lai V. Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. Br J Cancer. 2002 Jun 17;86(12):1854-7.</citation>
    <PMID>12085175</PMID>
  </reference>
  <reference>
    <citation>Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of Chronic Fatigue Syndrome. Neuropsychobiology. 1997;35(1):16-23.</citation>
    <PMID>9018019</PMID>
  </reference>
  <reference>
    <citation>Debouverie M, Pittion-Vouyovitch S, Louis S, Guillemin F. Validity of a French version of the fatigue impact scale in multiple sclerosis. Mult Scler. 2007 Sep;13(8):1026-32.</citation>
    <PMID>17895294</PMID>
  </reference>
  <reference>
    <citation>Montel SR, Bungener C. Coping and quality of life in one hundred and thirty five subjects with multiple sclerosis. Mult Scler. 2007 Apr;13(3):393-401. Epub 2007 Jan 29.</citation>
    <PMID>17439909</PMID>
  </reference>
  <reference>
    <citation>Cruciani RA, Dvorkin E, Homel P, Malamud S, Culliney B, Lapin J, Portenoy RK, Esteban-Cruciani N. Safety, tolerability and symptom outcomes associated with L-carnitine supplementation in patients with cancer, fatigue, and carnitine deficiency: a phase I/II study. J Pain Symptom Manage. 2006 Dec;32(6):551-9.</citation>
    <PMID>17157757</PMID>
  </reference>
  <reference>
    <citation>Gramignano G, Lusso MR, Madeddu C, Massa E, Serpe R, Deiana L, Lamonica G, Dessì M, Spiga C, Astara G, Macciò A, Mantovani G. Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. Nutrition. 2006 Feb;22(2):136-45.</citation>
    <PMID>16459226</PMID>
  </reference>
  <reference>
    <citation>Neri S, Pistone G, Saraceno B, Pennisi G, Luca S, Malaguarnera M. L-carnitine decreases severity and type of fatigue induced by interferon-alpha in the treatment of patients with hepatitis C. Neuropsychobiology. 2003;47(2):94-7.</citation>
    <PMID>12707492</PMID>
  </reference>
  <reference>
    <citation>Rebouche CJ. Kinetics, pharmacokinetics, and regulation of L-carnitine and acetyl-L-carnitine metabolism. Ann N Y Acad Sci. 2004 Nov;1033:30-41. Review.</citation>
    <PMID>15591001</PMID>
  </reference>
  <reference>
    <citation>Plioplys AV, Plioplys S. Serum levels of carnitine in chronic fatigue syndrome: clinical correlates. Neuropsychobiology. 1995;32(3):132-8.</citation>
    <PMID>8544970</PMID>
  </reference>
  <reference>
    <citation>Cruciani RA, Dvorkin E, Homel P, Culliney B, Malamud S, Shaiova L, Fleishman S, Lapin J, Klein E, Lesage P, Portenoy R, Esteban-Cruciani N. L-carnitine supplementation for the treatment of fatigue and depressed mood in cancer patients with carnitine deficiency: a preliminary analysis. Ann N Y Acad Sci. 2004 Nov;1033:168-76.</citation>
    <PMID>15591014</PMID>
  </reference>
  <reference>
    <citation>Taglialatela G, Navarra D, Cruciani R, Ramacci MT, Alemà GS, Angelucci L. Acetyl-L-carnitine treatment increases nerve growth factor levels and choline acetyltransferase activity in the central nervous system of aged rats. Exp Gerontol. 1994 Jan-Feb;29(1):55-66.</citation>
    <PMID>8187841</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2010</study_first_submitted>
  <study_first_submitted_qc>June 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2010</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Sclerosis/complications</keyword>
  <keyword>Fatigue Syndrome</keyword>
  <keyword>Chronic/drug therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

